ABOUT 870 BIOSIMILARS are reportedly in development, and many more are likely when more patents expire. It remains to be seen how this market will shake out from a regulatory and from a pricing perspective.
http://lnkd.in/Jkkd75
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022